newest glp 1 medication Comparing Ozempic, Wegovy and Other GLP-1 Drugs The Next Wave of Obesity

In December 2025, the TRIUMPH-4 trial reported that retatrutide 12 mg achieved a remarkable 28.7% mean weight loss at 68 weeks in patients with obesity and knee osteoarthritis, with substantial pain relief as well ( [71] )

That said, if medication nonadherence was a major factor for the blunted glycemic outcomes, the question remains why GLP-1 analog therapy did mediate significant weight loss, especially in women and SSRI users

The company highlighted its equal partnership with Roche for co-development and co-commercialization with 50/50 profit sharing in the U.S

Both are precursors to NAD+, but they differ in side effect profiles and metabolic pathways

C.CabauatanP

Comparison between surrogate indexes of insulin sensitivity and resistance and hyperinsulinemic euglycemic clamp estimates in mice